At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Carboplatin +2 moredrug
Likely dose
Paclitaxel 175 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
In Brief
A Phase 2 clinical trial evaluating Carboplatin, Paclitaxel, and 1 other intervention for Endometrial Cancer. Completed, enrolled 38 participants across 1 site.
Detailed Summary
Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionJan 2017
TodayJul 2026
First PostedAug 9, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 3, 2017
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 18.9 years ago
Interventions
Carboplatindrug
AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
Paclitaxeldrug
175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
bevacizumabdrug
15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.